Clinical Trials Logo

Pathological Processes clinical trials

View clinical trials related to Pathological Processes.

Filter by:
  • None
  • Page 1

NCT ID: NCT04073290 Recruiting - Liver Diseases Clinical Trials

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

PEARL
Start date: January 21, 2020
Phase: Phase 4
Study type: Interventional

Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration as minimal HE (MHE), covert HE (grade I), or overt HE (OHE, grade II-IV). Liver cirrhosis is the most common cause of portal hypertension (PH). Patients who develop complications of PH, like variceal bleeding or refractory ascites, can benefit from a Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement. Unfortunately, post-TIPS HE is a common and often severe complication. Incidence of new onset or worsening of HE after TIPS is approximately 20-45%. Currently there is no strategy to prevent post-TIPS HE.

NCT ID: NCT02681913 Recruiting - Cardiomyopathies Clinical Trials

Adenosine as an Adjunct to Blood Cardioplegia

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Myocardial protection is a major issue in cardiac surgery, since inadequate protection increases the risk of postoperative cardiac dysfunction. The main principle of myocardial protection in cardiac surgery is to preserve myocardial function by preventing ischemia with blood cardioplegia . Previous studies have shown that adenosine as an adjunct to blood cardioplegia can be safely used in cardiac surgery. In the Amphia Hospital, adenosine is already used as standard care as an initial cardioplegic bolus in minimally invasive port access operations. Whether, adenosine as an adjunct to intermittent warm blood cardioplegia, has an added value remains unclear. Therefore the investigators would like to investigate the effect of the addition of adenosine to standard intermittent warm blood cardioplegia in patients scheduled for minimally invasive, port access operations (mitral valve surgery). Half of the participants will receive standard intermittent warm blood cardioplegia, while the other half will receive intermittent warm blood cardioplegia enriched with adenosine.

NCT ID: NCT01092754 Completed - Clinical trials for Pathological Processes

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients

Start date: May 2002
Phase: Phase 4
Study type: Interventional

The objective of this study is to characterize the safety, efficacy and pharmacokinetic profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient population.

NCT ID: NCT00527670 Terminated - Clinical trials for Pathological Processes

Pilot Study to Identify the Influence of Genetic Profile Aberrations on Patients With Recurrent Hernias

Start date: August 2007
Phase: N/A
Study type: Observational

The aim of this study is to compare collagen composition in the skin and fascia of patients with recurrent or incisional hernias versus normal controls. We will identify potential genes responsible for genetic alterations in collagen deposition by using gene chip analysis of the tissue obtained and comparing the hernia group versus controls. The ultimate goal of this study is to identify target genes which may help us eventually predict which patients are at risk for developing post-operative hernias.